For GT Diagnostics, 2023 marks a pivotal year in transforming the way Alzheimer’s Disease (AD) is diagnosed and treated. Our well-being app, HiPAL, commercially launched this summer, is a testament to how digital tools can assist with cognitive monitoring. Available in multiple countries including the U.S. and the UK, HiPAL enables individuals to evaluate their cognitive health within the comfort of their own homes, making early detection of cognitive changes more accessible than ever before. Furthermore, the early positive feedback for HiPAL Pro, our professional-grade app designed for clinicians and neurologists, demonstrates its potential as a reliable diagnostic aid in medical settings.
Our advancements in digital diagnostic tools are closely aligned with significant strides in the treatment landscape, particularly the latest therapeutics that have shown promise in slowing down the disease’s progression. By facilitating earlier and more straightforward diagnosis, we are not just making it easier for individuals to seek help at the onset of symptoms, but we’re also opening doors for more effective treatments across various stages of the disease. In collaboration with researchers and medical professionals, we at GT Diagnostics are committed to ensuring that it’s never too early, never too late to act against Alzheimer’s Disease.
Read the latest UK BioIndustry Association article featuring GT Diagnostics CEO, Professor Bjoern Schelter and Head of Medical Affairs and Medical Oversight Lead at TauRx, Dr. Sonya Miller.
